SLC5A2 and fatty liver disease: SGLT2 inhibitors also mediates a metabolic switch from glucose to lipid utilization [68], and given the bi-directional relationship between fatty liver and CV disease [3], it is plausible that the reduction in hepatic triglyceride we observed in our study contributed in part to the improvement in cardiac contractile function.